Curie Brief
Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.
News
Being frail with rheumatoid arthritis significantly ups your cancer odds. A new study of U.S. veterans found that frail RA patients had nearly double the cancer incidence of their robust counterparts, and higher cancer mortality too. Researchers say frailty screening could be a practical tool for identifying older RA patients who need closer cancer surveillance.
Frailty and RA: A cancer risk combo worth watching
A retrospective study of 2,723 U.S. military veterans with rheumatoid arthritis (RA) has found that frailty is independently associated with significantly higher cancer incidence and mortality. Published in Arthritis Care & Research, the findings suggest that frailty assessment could serve as a clinically accessible tool to better identify which RA patients need closer cancer monitoring — on top of the already elevated malignancy risk that comes with the disease.
Researchers used the Veterans Affairs Frailty Index (VAFI) to classify patients as robust, pre-frail, or frail, then tracked cancer outcomes over two decades of registry data. The dose-dependent relationship was clear: the frailer the patient, the higher the cancer risk. Importantly, this association held up even after adjusting for smoking, medications, and other comorbidities.
By the Numbers
Why it matters: RA patients already face elevated cancer risk due to chronic inflammation and shared risk factors like smoking. Adding frailty as a risk-stratification tool — especially in older patients — could help rheumatologists prioritize cancer screening more effectively. However, experts caution that this approach needs validation across more diverse RA populations before it becomes standard practice.
